lerafaon
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00024661)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase RAFANTISENSE INHIBITOR
RAF1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lerafaon
- lerafaon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00100672 | Phase 1 | Dec 1, 2004 | Insys Therapeutics Inc |
| NCT00024648 | Phase 1 | Mar 1, 2001 | Georgetown University, Insys Therapeutics Inc |
| NCT00024661 | Phase 1 | Mar 1, 2001 | Georgetown University, Insys Therapeutics Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Insys Therapeutics Inc | For profit | 3 | 3 | 1 | 2001 |
| Georgetown University | Academic/Hospital | 2 | 0 | 1 | 2001 |
2 organizations
Page 1 / 1